News

The transaction is expected to close during the second quarter of 2009, subject to customary closing conditions. Piedmont Research Center (PRC) offers non-Good Laboratory Practice preclinical efficacy testing

The partnership combines Carroll Hospital Group’s new medical-surgical bed, Spirit Select, with Kinetic Concepts’s broad mattress replacement portfolio, which includes multiple products that are believed to provide superior

Sepracor, a research-based pharmaceutical company, has submitted a new drug application to the FDA for the use of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset

Under the two-year agreement, Kingchem will act as an agent to find a US pharmaceutical company to co-develop Sinobiopharma’s Chinese patented new version of cisatracurim besylate, a non-depolarizing

According to PPD, the acquisition expands its compound partnering program into dermatology, initially in the indications of psoriasis, atopic dermatitis and acne. With the acquisition, PPD gains a

The company expects to earn gross proceeds of approximately $31 million, before deducting placement agent’s fees and estimated offering expenses. The investors have agreed to purchase the units

Taro’s carbamazepine extended-release tablets are bioequivalent to the reference listed drug Tegretol-XR tablets of Novartis Pharmaceuticals, a prescription pharmaceutical product used for treating seizures. The FDA has informed

Alexion Pharmaceuticals, a biopharmaceutical company, has submitted a new drug application for Soliris as a treatment for patients with paroxysmal nocturnal hemoglobinuria to Japan’s Pharmaceuticals and Medical Devices

Nitec Pharma, a Switzerland-based specialty pharma company, has granted an exclusive license to Mundipharma International for the distribution of Lodotra in Europe. Under the terms of the agreement,